Hyris developed a rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with Duke-NUS Medical School. This new solution leverages the power of the renowned HYRIS bCUBE™ and the whole Hyris SystemTM. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.